Phase Forward Signs Multi-Year Agreement with Major Pharmaceutical Company Gedeon Richter
Waltham, MA
Phase Forward announced a multi-year agreement with Gedeon Richter Plc., a leading pharmaceutical company in Central-Eastern Europe. Gedeon Richter plans to adopt Phase Forward’s Clintrial™ product for its clinical trial data management activities.
Founded in 1901 and headquartered in Budapest, Hungary, Gedeon Richter’s organization manufactures and markets generic pharmaceutical products for the treatment of a variety of therapy areas including gynecology and cardiology. After completing a competitive product review, Gedeon Richter selected Phase Forward.
“We know that we are collaborating with the premier technology provider for clinical trials – and we look forward to garnering the benefits inherent in greater drug trial efficiencies,” said György Németh, medical director, Gedeon Richter.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
